BriaCell Therapeutics Corp. (NASDAQ:BCTX – Get Rating)’s stock price dropped 4.6% on Wednesday . The company traded as low as $5.95 and last traded at $6.03. Approximately 101,680 shares were traded during trading, a decline of 44% from the average daily volume of 181,220 shares. The stock had previously closed at $6.32.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright restated a “buy” rating and set a $25.00 price objective on shares of BriaCell Therapeutics in a research note on Friday, February 24th.
BriaCell Therapeutics Price Performance
The business’s 50 day moving average price is $6.93 and its 200 day moving average price is $6.49. The stock has a market capitalization of $91.09 million, a P/E ratio of -2.79 and a beta of 1.23.
Institutional Trading of BriaCell Therapeutics
About BriaCell Therapeutics
BriaCell Therapeutics Corp. is an immuno-oncology biotechnology company, which engages in the development of immunotherapies for treatment of cancer. Its technologies include Bria-IMT and Bria-OTS. The company was founded by Charles L. Wiseman and Isaac B. Maresky on July 26, 2006 and is headquartered in West Vancouver, Canada.
- Get a free copy of the StockNews.com research report on BriaCell Therapeutics (BCTX)
- Big Lots Becomes A Stomach Churning Value Play
- The Melt-Up In Marvell Is On; But Don’t Chase It Higher
- Is Apple a Growth Stock or a Value Stock?
- Costco’s Earnings Call Reassure Economists, Recession Cancelled
- Hot Inflation, What It Means For The Summer Rally
Receive News & Ratings for BriaCell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BriaCell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.